IL17A and systemic-onset juvenile idiopathic arthritis: Biologic agents modulating the action of IL-17 are in various stages of investigation in the treatment of psoriasis, psoriatic arthritis, and rheumatoid arthritis75 and may be worth considering in the treatment of sJIA patients with chronic arthritis.